GlassScriptPhysician profile
John Z Hall
NPI 1215961180
$23,139.36
in general payments reported to CMS, 2019-2025
63 companies · $2,834 in 2025
The $2,834 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,915 · 2020: $2,359 · 2021: $4,026 · 2022: $4,347 · 2023: $3,460 · 2024: $3,200 · 2025: $2,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,418 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,418.15 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,526.74 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,970.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,932.33 | 2019-2025 | |
| Amgen INC. | $1,772.15 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $1,389.63 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $1,347.69 | 2021-2025 | |
| Lilly USA, LLC | $1,341.99 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $1,225.42 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $879.54 | 2019-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $867.19 | 2019-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $831.95 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $502.35 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $439.69 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $424.79 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $359.61 | 2019-2024 | Xifaxan, Trulance |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.